Joseph Anthony Dottino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 4 | 2023 | 1353 | 1.140 |
Why?
|
| Ovarian Neoplasms | 8 | 2023 | 4838 | 1.010 |
Why?
|
| Endometrial Hyperplasia | 1 | 2023 | 97 | 0.850 |
Why?
|
| Drug Labeling | 1 | 2020 | 233 | 0.610 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2016 | 28 | 0.560 |
Why?
|
| Levonorgestrel | 1 | 2016 | 77 | 0.560 |
Why?
|
| Premenopause | 1 | 2020 | 1033 | 0.550 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 576 | 0.500 |
Why?
|
| Contraceptive Agents, Female | 1 | 2016 | 135 | 0.500 |
Why?
|
| Models, Economic | 2 | 2016 | 713 | 0.490 |
Why?
|
| Estrogens | 1 | 2020 | 1566 | 0.450 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 379 | 0.430 |
Why?
|
| Drug Approval | 1 | 2019 | 742 | 0.420 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1861 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 2020 | 0.290 |
Why?
|
| Obesity | 3 | 2023 | 12745 | 0.290 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3396 | 0.290 |
Why?
|
| Hospitals | 1 | 2019 | 3952 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 5 | 2020 | 5391 | 0.260 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2266 | 0.250 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1584 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.190 |
Why?
|
| Ostomy | 1 | 2020 | 27 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 11725 | 0.170 |
Why?
|
| Splenectomy | 1 | 2020 | 395 | 0.160 |
Why?
|
| Diaphragm | 1 | 2020 | 349 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2728 | 0.160 |
Why?
|
| Endometrium | 1 | 2020 | 424 | 0.150 |
Why?
|
| Hepatectomy | 1 | 2020 | 550 | 0.140 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 547 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2020 | 804 | 0.130 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 1254 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2015 | 108 | 0.130 |
Why?
|
| United States | 5 | 2020 | 69872 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 13695 | 0.110 |
Why?
|
| Female | 14 | 2023 | 380194 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2023 | 12720 | 0.110 |
Why?
|
| Markov Chains | 1 | 2015 | 969 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 11031 | 0.100 |
Why?
|
| Intestines | 1 | 2020 | 1924 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6895 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 2219 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1770 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2015 | 927 | 0.090 |
Why?
|
| Health Surveys | 1 | 2019 | 4037 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
| Humans | 14 | 2023 | 744343 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2010 | 324 | 0.080 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2010 | 336 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 1513 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2019 | 10252 | 0.070 |
Why?
|
| Length of Stay | 1 | 2019 | 6309 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5317 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 665 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 77449 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 3086 | 0.050 |
Why?
|
| Middle Aged | 5 | 2019 | 213383 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15295 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 35136 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 57776 | 0.050 |
Why?
|
| Mass Screening | 1 | 2016 | 5255 | 0.050 |
Why?
|
| Aged | 5 | 2020 | 163280 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6364 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 40561 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3479 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.040 |
Why?
|
| Quality of Life | 1 | 2019 | 12804 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 711 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2015 | 228 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 63114 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11524 | 0.030 |
Why?
|
| Polymers | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 72290 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1508 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2503 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 801 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 2938 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 1781 | 0.020 |
Why?
|
| Gene Expression | 1 | 2023 | 7799 | 0.020 |
Why?
|
| Cisplatin | 1 | 2015 | 1662 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2015 | 1708 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 214055 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6538 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 21827 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 24260 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 1769 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12788 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12354 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 168757 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 81183 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 20947 | 0.010 |
Why?
|